Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Report Date: February 17, 2026
Reporting Period: Fourth quarter and full year ended December 31, 2025
This filing serves as a notification that the Company announced its financial results for the specified period. The detailed results are contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: Specific values for these metrics are not present in the filing text provided; they are referenced only as being included in the attached Exhibit 99.1.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to prior periods. It only confirms the announcement of results for the fourth quarter and full year 2025.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. These items are presumed to be detailed in the press release (Exhibit 99.1) referenced in Item 2.02.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 17, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical or commercial milestones achieved during Q4 2025 and the full year 2025.
- Check for any updated financial guidance or operational outlook provided in the press release.
- Confirm the status of the Company's cash runway and any recent financing activities mentioned in the full report.